NMNAT overexpression has had some success in models of glaucoma (Kitaoka et al., 2013), though if energy support is the goal, a very promising candidate is the NAD+ precursor nicotinamide riboside (Figure 4). The gene discussed is NMNAT1; the disease is glaucoma.